This trial will compare the different tyrosine kinase inhibitors, with and without ruxolitinib, to see how well they work in treating patients with chronic myeloid leukemia.
1 Primary · 7 Secondary · Reporting Duration: Up to 5 years
Active Control
Experimental Treatment
84 Total Participants · 4 Treatment Groups
Primary Treatment: Ruxolitinib Phosphate · No Placebo Group · Phase 2
Age 18+ · All Participants · 10 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you: